Phase 3 N=500 A Six-Week Safety Study of an Investigational Ophthalmic Solution
Allergic Conjunctivitis
Primary: Adverse Events — 0; 0; 0; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=14 Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Cancer
Primary: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) by Dose — 6; 91; 2; 64 Participants
N/A N=86 Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian Federation
Secondary Hyperparathyroidism
Primary: The Percentage of Participants Who Reached a Target Level of Intact Parathyroid Hormone (iPTH) (150-300 pg/mL) Post-baseline at Least Once During the Study — 60.5…
Phase 2 N=32 Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients
Prostate Cancer
Primary: Number of Participants With Overall Clinical Benefit (OCB), Defined as the Sum of Complete Response (CR), Partial Response (PR), and Stable Disease (SD) Divided by the…
Phase 2 N=12 The Effect of High-dose Silybin-phytosome in Men With Prostate Cancer
Prostate Cancer
Primary: Measurable Silibinin Tissue Levels — 3 Participants
Phase 2 N=51 Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Anaplastic Large Cell Lymphoma · Recurrent Adult Burkitt Lymphoma · Recurrent Adult Diffuse Large Cell Lymphoma
Primary: Objective Overall Response Rate — 14; 0 participants — p=0.022
N/A N=178 Randomized Trial Evaluating Performance of the Trevo Retriever Versus the Merci Retriever in Acute Ischemic Stroke
Ischemic Stroke
Primary: Primary Efficacy Endpoint — 54; 76 participants
Phase 1 N=13 Determine MTD and to Evaluate pk, Safety/Tolerability and Efficacy Profiles of Hocena® in NSCLC Subjects
Non-small Cell Lung Cancer
Primary: To Determind the Maximum Tolerable Dose for Antroquinonol — 600 mg
N/A N=304 Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users
HIV · Opioid Dependence
Primary: Demonstrated Drug Risk Reduction Skills (0-100%) — 40.60; 42.75 Percentage of correct steps
N/A N=41 Effect of Early Skin to Skin Contact on Breast Feeding Behaviour in Term Newborns: A Randomized Controlled Trial
Breastfeeding
Primary: The Median Breast Feeding Score — 8; 9 scores
Phase 2 N=40 Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer
Small Cell Lung Cancer
Primary: Determine the Proportion of Previously Treated Small Cell Lung Cancer (SCLC) Patients Whose Disease Has Not Progressed Following 6-weeks (2 Cycles) of Treatment With…
Phase 3 N=855 Trial of Adjuvant Chemotherapy for Gastric Cancer
Stomach Cancer
Primary: Relapse-free Survival Rate — 67.0; 64.9 percentage of participants
N/A N=30 A Prospective, Multi-Center, Single-Arm Study of the Veriset™ Hemostatic Patch in Controlling Bleeding in Soft Tissue
Non-emergent, Soft Tissue Procedures, Performed Via an Open Approach
Primary: Percent Success in Obtaining Hemostasis Following Veriset Hemostatic Patch Treatment — 29 participants — p=<0.0001
Phase 4 N=77 Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects
Type 2 Diabetes Mellitus
Primary: Comparison of Changes in Fasting Serum Glucose (FSG)With Pioglitazone and Metformin — 6.9; 6.2; 5.4; 6.5 mmol/l — p=<0.05
Phase 3 N=413 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
Brain and Central Nervous System Tumors
Primary: Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors — 79.2; 83.3; 69.6; 86.7 probability of PFS at 2 years — p=0.8001